[go: up one dir, main page]

DK0416951T3 - Lægemidler indeholdende salmeterol og fluticason - Google Patents

Lægemidler indeholdende salmeterol og fluticason

Info

Publication number
DK0416951T3
DK0416951T3 DK90309846.5T DK90309846T DK0416951T3 DK 0416951 T3 DK0416951 T3 DK 0416951T3 DK 90309846 T DK90309846 T DK 90309846T DK 0416951 T3 DK0416951 T3 DK 0416951T3
Authority
DK
Denmark
Prior art keywords
fluticasone
medicines containing
salmeterol
containing salmeterol
inhalation
Prior art date
Application number
DK90309846.5T
Other languages
Danish (da)
English (en)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0416951(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0416951T3 publication Critical patent/DK0416951T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK90309846.5T 1989-09-08 1990-09-07 Lægemidler indeholdende salmeterol og fluticason DK0416951T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
DK0416951T3 true DK0416951T3 (da) 1994-02-14

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90309846.5T DK0416951T3 (da) 1989-09-08 1990-09-07 Lægemidler indeholdende salmeterol og fluticason

Country Status (20)

Country Link
EP (1) EP0416951B1 (fr)
JP (1) JP3042867B2 (fr)
AT (1) ATE99941T1 (fr)
BE (1) BE1003053A3 (fr)
CA (1) CA2024916C (fr)
CH (1) CH680983C9 (fr)
DE (2) DE19975040I2 (fr)
DK (1) DK0416951T3 (fr)
ES (1) ES2062392T3 (fr)
FR (1) FR2651677B1 (fr)
HK (1) HK18695A (fr)
HU (1) HU211272A9 (fr)
IE (1) IE65535B1 (fr)
IL (1) IL95590A (fr)
IT (1) IT1241996B (fr)
LU (1) LU90392I2 (fr)
NL (1) NL990012I2 (fr)
NZ (1) NZ235221A (fr)
PH (1) PH27594A (fr)
SG (1) SG166294G (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
WO1993011773A1 (fr) * 1991-12-18 1993-06-24 Aktiebolaget Astra Nouvelle combinaison de formoterol et de budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
WO2001019342A2 (fr) 1999-09-11 2001-03-22 Glaxo Group Limited Preparation pharmaceutique renfermant du propionate de fluticasone
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
SI1305329T2 (sl) * 2000-08-05 2015-07-31 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CA2445839A1 (fr) 2001-04-30 2002-11-07 Glaxo Group Limited Derives anti-inflammatoires d'androstane 17.beta.-carbothioate ester avec un groupe cyclique en position 17.alpha
BRPI0212455B8 (pt) 2001-09-14 2021-05-25 Glaxo Group Ltd composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (fr) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation pour inhalation comprenant un glucocorticoïde et un agoniste de 2-adrénorécepteur béta
EP1471895B2 (fr) † 2002-02-04 2012-03-14 Glaxo Group Limited Formulation pour inhalation comprenant un glucocorticoide et un agoniste de 2-adrenorecepteur beta
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004052374A1 (fr) 2002-12-12 2004-06-24 Altana Pharma Ag Medicament combine
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
DK1658063T3 (da) 2003-08-06 2014-05-12 Galephar M F Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
US8567394B2 (en) 2006-12-22 2013-10-29 Almirall, S.A. Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
EP2991625A1 (fr) * 2013-04-29 2016-03-09 Sanofi SA Compositions pharmaceutiques inhalables et dispositifs inhalateurs contenant ces compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
DE19975040I2 (de) 2006-07-13
EP0416951B1 (fr) 1994-01-12
IT1241996B (it) 1994-02-02
CA2024916A1 (fr) 1991-03-09
FR2651677A1 (fr) 1991-03-15
CA2024916C (fr) 2002-07-09
HK18695A (en) 1995-02-17
BE1003053A3 (fr) 1991-11-05
NL990012I1 (nl) 1999-07-01
CH680983C1 (fr) 2008-06-25
NL990012I2 (nl) 1999-09-01
FR2651677B1 (fr) 1993-08-06
SG166294G (en) 1995-06-16
IL95590A (en) 1996-06-18
LU90392I2 (fr) 1999-06-28
JPH03167120A (ja) 1991-07-19
ATE99941T1 (de) 1994-01-15
EP0416951A1 (fr) 1991-03-13
IL95590A0 (en) 1991-09-16
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
JP3042867B2 (ja) 2000-05-22
CH680983A5 (fr) 1992-12-31
PH27594A (en) 1993-08-31
CH680983C9 (fr) 2008-08-15
IT9048260A0 (it) 1990-09-07
NZ235221A (en) 1992-11-25
IE903256A1 (en) 1991-03-13
DE69005951D1 (de) 1994-02-24
IE65535B1 (en) 1995-11-01
DE69005951T2 (de) 1994-05-26
HU211272A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
DK0416951T3 (da) Lægemidler indeholdende salmeterol og fluticason
DE69002718D1 (de) Medikamente.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
CA2123909A1 (fr) Nouvelle combinaison de formoterol et de budesonide
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
ZA96779B (en) Calcitonin salmon analogues their preparation medicinal use and use as analytical agents
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
MY111155A (en) Medicaments
JPS6438027A (en) Remedy for cancer
RU93003454A (ru) Лекарственный препарат